Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda, Wakamoto Focus On Specific Purpose OTC Gastro Drug Market

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical, Wakamoto Pharmaceutical and other Japanese drug makers see a potential for increased sales in a declining market by offering over-the-counter gastrointestinal drugs. They are focusing on drugs that are easier to distinguish by symptom and age. Takeda is offering a drug specific to three symptoms and Wakamoto is offering one geared toward people whose digestive systems have deteriorated with age. Takeda's drugs are classified as second-group OTCs, meaning they have a medium-level risk of side effects. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072931

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel